October 29, 2007:  Financial Results

HIGHLIGHTS:

1. 2nd Quarter Income up 24% (YoY). Net Profit up 28% (YoY).

2. 1st Half Income up 18% (YoY). Net Profit up 34% (YoY). 

3. Interim Dividend of 35% declared.

Q2 FINANCIAL RESULTS

The net total income for the 2nd quarter has gone up by 24% to Rs.300.45 crores as against Rs.242.98 crores in the same period previous financial year. Export Sales have increased by 24% to Rs.138.19 crores.

The Net Profit for the 2nd Quarter has gone up by 28% to Rs.45.42 crores as against Rs.35.40 crores in the same period of previous year. The fully diluted Earnings Per Share for the quarter works out to Rs.18.05 per share of Rs.10/- each.

The Board has declared an interim dividend of 35% (Rs.3.50 per share) for the financial year 2007-08.

Q2 at a glance

 

(Rs. Crores)
2nd Quarter ended	30.09.2007	30.09.2006	Growth
Net Total Income	300.45	242.98	24 %
Export Income	138.19	111.21	24%
Profit before Tax	59.77	45.54	31%
Net Profit	45.42	35.40	28%
Earnings per share (Rs.)	18.05	14.15	28%

 

(Rs. Crores)
Half Year ended	30.09.2007	30.09.2006	Growth
Net Total Income	547.67	465.02	18%
Export Income	247.49	216.04	15%
Profit before Tax	103.64	75.48	37%
Net Profit	80.14	59.74	34%
Earnings per share (Rs.)	31.85	23.89	33%

Ipca Laboratories is a backward integrated, fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for nearly half of Company's income.

Premchand Godha
Managing Director

Encl: Unaudited Financial Results.

Back